Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more
Hansa Biopharma AB (publ) - Asset Resilience Ratio
Hansa Biopharma AB (publ) (HNSBF) has an Asset Resilience Ratio of 12.65% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2021)
This chart shows how Hansa Biopharma AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hansa Biopharma AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $99.27 Million | 12.65% |
| Total Liquid Assets | $99.27 Million | 12.65% |
Asset Resilience Insights
- Moderate Liquidity: Hansa Biopharma AB (publ) has 12.65% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Hansa Biopharma AB (publ) Industry Peers by Asset Resilience Ratio
Compare Hansa Biopharma AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Hansa Biopharma AB (publ) (2013–2021)
The table below shows the annual Asset Resilience Ratio data for Hansa Biopharma AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 23.46% | $237.62 Million | $1.01 Billion | +6.86pp |
| 2020-12-31 | 16.60% | $238.14 Million | $1.43 Billion | -46.54pp |
| 2019-12-31 | 63.14% | $419.40 Million | $664.24 Million | +18.82pp |
| 2018-12-31 | 44.32% | $418.75 Million | $944.82 Million | +39.18pp |
| 2017-12-31 | 5.14% | $34.98 Million | $680.41 Million | -7.73pp |
| 2016-12-31 | 12.87% | $39.99 Million | $310.67 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $224.09 Million | -- |
| 2014-12-31 | 0.00% | $1.00 | $54.31 Million | +4.07pp |
| 2013-12-31 | -4.07% | $-2.06 Million | $50.78 Million | -- |